Form 4: Whitehawk Therapeutics Director Behzad Aghazadeh Granted 40,006 Stock Options

A recent SEC Form 4 filing reveals that Behzad Aghazadeh, a director and 10% owner of Whitehawk Therapeutics, Inc., was granted 40,006 stock options with an exercise price of $2.04, vesting over one year or until the next annual meeting.

Summary

• Behzad Aghazadeh, a director and 10% owner of Whitehawk Therapeutics, Inc. (WHWK), along with Avoro Capital Advisors LLC and Avoro Ventures LLC, reported the acquisition of derivative securities.
• On June 12, 2025, Dr. Aghazadeh was granted 40,006 stock options.
• Each option grants the right to buy one share of Whitehawk Therapeutics Common Stock at an exercise price of $2.04.
• The options were acquired at a price of $0, indicating they were granted as compensation or incentive.
• The options will vest 100% on the earlier of the one-year anniversary of the grant date (June 12, 2025) or the day immediately prior to the next annual meeting of stockholders following the grant date, contingent on Dr. Aghazadeh remaining a Service Provider.
• The options have an expiration date of June 12, 2035.
• Following this transaction, Dr. Aghazadeh beneficially owns 40,006 derivative securities.
• A Power of Attorney was executed on April 25, 2025, by Behzad Aghazadeh, authorizing specific individuals to file SEC reports on his behalf.

Sentiment

Score: 6

Explanation: The document reports a standard insider transaction (stock option grant) which is generally positive for aligning interests but does not contain significant new operational or financial news to dramatically shift sentiment. It's a neutral-to-slightly positive event.

Positives

• Granting of stock options to a director and significant shareholder (Behzad Aghazadeh) aligns management and shareholder interests, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long-term incentive horizon.

Negatives

• The exercise of these options in the future could lead to a slight dilution of existing shareholder equity, although the amount is relatively small (40,006 shares).

Risks

• Vesting of the stock options is contingent upon Behzad Aghazadeh continuing to be a "Service Provider" to Whitehawk Therapeutics, Inc.
• The value of the options is dependent on the future market price of Whitehawk Therapeutics' common stock exceeding the exercise price of $2.04.

Future Outlook

The vesting schedule for the granted stock options indicates a forward-looking incentive structure, aligning the director's interests with the company's performance over the next year or until the next annual meeting.

Management Comments

• "The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."
• "Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."
• "Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of the Issuer by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer."

Industry Context

This Form 4 filing is a routine disclosure of insider equity transactions, common across all publicly traded companies. It reflects standard compensation practices for directors, aiming to align their incentives with shareholder value creation, particularly in the biotechnology or pharmaceutical sector where long-term development cycles are prevalent.

Comparison to Industry Standards

• The grant of stock options to a director is a standard practice in corporate compensation across various industries, including biotechnology.
• The exercise price of $2.04, while specific to Whitehawk Therapeutics, is typical for options granted at or near the market price at the time of grant.
• The vesting schedule (one year or next annual meeting) is also a common short-to-medium term incentive structure, comparable to practices at companies like Moderna (MRNA) or BioNTech (BNTX) for their executive and board compensation, though the specific number of options and exercise price would vary based on company size and stock valuation.

Corporate Governance

Related Party Transactions

• The transaction involves a stock option grant to Behzad Aghazadeh, who is a director and 10% owner, and also controls Avoro Capital Advisors LLC and Avoro Ventures LLC, which are also listed as reporting persons and deemed directors by deputization. This constitutes a related party transaction as it involves compensation to a key insider and affiliated entities.

Stakeholder Impact

• Shareholders: Potential for slight future dilution upon exercise of options, but also benefit from improved alignment of director's interests with long-term stock performance.
• Employees: No direct impact mentioned, but the use of an equity incentive plan suggests a broader framework for employee incentives might exist.
• Management: Behzad Aghazadeh receives a significant equity incentive, aligning his financial interests with the company's success.

Next Steps

• The stock options will vest on the earlier of June 12, 2026 (one-year anniversary of grant) or the day prior to the next annual meeting of stockholders.
• Behzad Aghazadeh or his authorized attorneys-in-fact will continue to file required SEC reports (Forms 3, 4, 5, Schedules 13D, 13G, Forms 144) regarding his holdings and transactions in Whitehawk Therapeutics securities.

Key Dates

Recommendation

Keywords

Whitehawk Therapeutics, WHWK, SEC Form 4, Stock Options, Beneficial Ownership, Director Compensation, Equity Incentive Plan, Behzad Aghazadeh, Avoro Capital Advisors, Avoro Ventures, Insider Trading, Corporate Governance